+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Changes in Plasma Apolipoprotein B-Containing Lipoparticle Levels Following Therapy with Fluvastatin and Cholestyramine

Changes in Plasma Apolipoprotein B-Containing Lipoparticle Levels Following Therapy with Fluvastatin and Cholestyramine

American Journal of Cardiology 76(2): 65A-70A

Epidemiologic studies have demonstrated that apolipoprotein (apo) B-containing lipoparticles (LpE:B, LpC-III:B) are associated with the risk of coronary artery disease whereas apo A-1-containing lipoparticles (LpA-1) are protective against coronary artery disease. The effect on lipoparticle levels of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor fluvastatin, in combination with cholestyramine, was assessed in a double-blind randomized study. A total of 144 patients with primary hypercholesterolemia were recruited, who had successfully completed an original study comparing the effects of fluvastatin and cholestyramine on plasma lipoparticle levels. All subjects fulfilled the following inclusion criteria: plasma low density lipoprotein cholesterol (LDL-C) levels gt 160 mg/dL, with premature coronary artery disease and 2 associated risk factors; or LDL-C gt 190 mg/dL, no coronary artery disease, and triglycerides lt 300 mg/dL, after a lipid-lowering diet. Patients were randomized to 1 of 3 combination therapy groups: fluvastatin 20 mg/day plus cholestyramine 4 g/day; fluvastatin 20 mg/day plus cholestyramine 8 g/day; and fluvastatin 20 mg/day plus cholestyramine 16 g/day. The study length was 6 weeks and patients were examined at 3-week intervals. Fluvastatin plus cholestyramine produced a significant (p lt 0.001), dose-dependent reduction in levels of cholesterol (range, -29 to -34%), LDL-C (range, -30 to -44%), apo B (range, -23 to -34%), and apo E (range, -33 to -43%). LpE:B levels were also reduced (range, -19 to -26%), but not significantly. Reductions in levels of apo C-III (range, -6.7 to -21%) and LpC-III:B (range, -32 to -28%) were only statistically significant at the lower doses of cholestyramine. The combination therapy produced a clear, dose-dependent increase in apo A-1 (range, 8-14%; p lt 0.001) and LpA-1 (range, 13-32%; p lt 0.001). In conclusion, treatment combining 20 mg/day of fluvastatin with cholestyramine produces a major beneficial change in the lipoprotein and coronary artery disease risk profile in hypercholesterolemic subjects, reducing the levels of atherogenic apo B-containing particles and increasing the levels of protective apo A-I-containing particles.

Please choose payment method:

(PDF emailed within 1 workday: $29.90)

Accession: 008281720

Download citation: RISBibTeXText

Related references

Changes in plasmaapolipoprotein B-containing lipoparticle levels following therapy with fluvastatin and cholestyramine. American Journal of Cardiology 76(1-2): 65-70, 1995

Serum lipid, apolipoprotein and lipoparticle levels in the human fetus. Prenatal Diagnosis 15(3): 225-228, 1995

Effect of fluvastatin on plasma apolipoprotein-B-containing particles, including lipoprotein(a). European Fluvastatin Study Group. Journal of Internal Medicine. Supplement 736: 95, 1994

Comparison of the effect of fluvastatin, an hydroxymethyl glutaryl coenzyme A reductase inhibitor, and cholestyramine, a bile acid sequestrant, on lipoprotein particles defined by apolipoprotein composition. Metabolism Clinical & Experimental. 44(11): 1447-1454, 1995

Treatment of familial hypercholesterolemia a controlled trial of the effects of pravastatin or cholestyramine therapy on lipoprotein and apolipoprotein levels. Journal of Internal Medicine 228(3): 241-248, 1990

Fluvastatin reduces levels of plasma apo B-containing particles and increases those of LpA-I. European Fluvastatin Study Group. American Journal of Medicine 96(6a): 32s-36s, 1994

Low-dose combined therapy with fluvastatin and cholestyramine in hyperlipidemic patients. Annals of Internal Medicine 120(7): 537-543, 1994

Treatment of patients with elevated plasma levels of low density lipoproteins with a cholestyramine tablet compared with cholestyramine powder. Current Therapeutic Research 52(2): 330-337, 1992

Cholestyramine and a fat-free diet lower apolipoprotein A-IV mRNA in jejunum and cholestyramine lowers apolipoprotein A-I mRNA in ileum of rats. Journal of Nutrition 124(5): 621-627, 1994

Efficacy and safety of triple therapy(fluvastatin-bezafibrate-cholestyramine) for severe familial hypercholesterolemia. American Journal of Cardiology 76(1-2): 84-88, 1995

Efficacy and safety of triple therapy (fluvastatin-bezafibrate-cholestyramine) for severe familial hypercholesterolemia. American Journal of Cardiology 76(2): 84a-88a, 1995

The efficacy of electroacupuncture therapy for weight loss changes plasma lipoprotein A, apolipoprotein A and apolipoprotein B levels in obese women. American Journal of Chinese Medicine 36(6): 1029-1039, 2008

Efficacy and safety of a combination fluvastatin-bezafibrate treatment for familial hypercholesterolemia: Comparative analysis with a fluvastatin-cholestyramine combination. American Journal of Medicine 96(5): 401-407, 1994

Long-term efficacy with fluvastatin as monotherapy and combined with cholestyramine (a 156-week multicenter study). French-Dutch Fluvastatin Study Group. American Journal of Cardiology 76(2): 41a-46a, 1995

Comparative effects of pravastatin simvastatin fenofibrate and cholestyramine on plasma apolipoprotein ai containing plasma lipoprotein particles. Journal of Drug Development 3(Suppl. 1): 103-106, 1990